DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway

Blood. 2001 Aug 1;98(3):834-41. doi: 10.1182/blood.v98.3.834.

Abstract

Exposure of hematopoietic cells to DNA-damaging agents induces cell-cycle arrest at G1 and G2/M checkpoints. Previously, it was shown that DNA damage-induced growth arrest of hematopoietic cells can be overridden by treatment with cytokine growth factors, such as erythropoietin (EPO) or interleukin-3 (IL-3). Here, the cytokine-activated signaling pathways required to override G1 and G2/M checkpoints induced by gamma-irradiation (gamma-IR) are characterized. Using factor-dependent myeloid cells stably expressing EPO receptor (EPO-R) mutants, it is shown that removal of a minimal domain required for PI-3K signaling abrogated the ability of EPO to override gamma-IR-induced cell-cycle arrest. Similarly, the ability of cytokines to override gamma-IR-induced arrest was abolished by an inhibitor of PI-3K (LY294002) or by overexpression of dominant-negative Akt. Moreover, the ability of EPO to override these checkpoints in cells expressing defective EPO-R mutants could be restored by overexpression of a constitutively active Akt. Thus, activation of a PI-3K/Akt signaling pathway is required for cytokine-dependent suppression of DNA-damage induced checkpoints. Together, these findings suggest a novel role for PI-3K/Akt pathways in the modulation of growth arrest responses to DNA damage in hematopoietic cells. (Blood. 2001;98:834-841)

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cell Cycle / drug effects*
  • Cell Cycle / radiation effects
  • Cell Line
  • DNA Damage / physiology*
  • Enzyme Activation
  • Erythropoietin / pharmacology
  • Gamma Rays
  • Hematopoietic Stem Cells / physiology*
  • Hematopoietic Stem Cells / radiation effects
  • Interleukin-3 / pharmacology
  • Mice
  • Mutation
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphatidylinositol 3-Kinases / pharmacology
  • Phosphatidylinositol 3-Kinases / physiology*
  • Protein Serine-Threonine Kinases*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins / pharmacology
  • Proto-Oncogene Proteins / physiology*
  • Proto-Oncogene Proteins c-akt
  • Receptors, Erythropoietin / genetics
  • Signal Transduction / drug effects

Substances

  • Interleukin-3
  • Proto-Oncogene Proteins
  • Receptors, Erythropoietin
  • Erythropoietin
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt